Recruiting

Heart Coherence Training

Sponsor:

Baylor College of Medicine

Code:

NCT05994664

Conditions

Vascular Ehlers-Danlos Syndrome

Eligibility Criteria

Sex: All

Age: 12 - 45

Healthy Volunteers: Not accepted

Interventions

Heartmath Intervention

Control Group

Study Details

Brief summary:

Vascular Ehlers-Danlos Syndrome (VEDS) is caused by pathogenic variants of the COL3A1 gene, resulting abnormal Type III collagen protein. This impacts the body's connective tissue and makes people with VEDS at high risk of spontaneous aortic and arterial rupture, pneumothorax, and hollow organ perforation across the age spectrum. Given this risk and high potential for lethality, VEDS is considered the most severe type of Ehlers-Danlos Syndrome. In addition, many patients experience chronic pain and fatigue, sleep disturbances, and mental health challenges. As is the case for many patients with chronic illness, stress, anxiety, and depression are often present over the course of the disease. Despite the antecedent, stress and anxiety trigger a sympathetic nervous system (SNS) response in the body, which, over a period of time, can have detrimental effects both physiologically and psychologically for patients. Recent studies have begun to use biofeedback techniques to teach patients non-pharmacological strategies for managing their autonomic nervous system. One such program, Heartmath®, has been successful in helping patients lower stress, anxiety, and systolic blood pressure. This pilot trial was established to assess the effectiveness of a virtually based heart coherence program in a population with a chronic aortopathy in an effort to establish a larger, multi-provider program that also encompasses other cardiovascular populations.

Conditions

Vascular Ehlers-Danlos Syndrome

Study ID

NCT05994664

Start date

Apr 1, 2024

Status verified date

Jun, 2024

Completion date

Jan 1, 2028

Anticipated

Primary completion date

Jun 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12 - 45

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must be diagnosed with Vascular Ehlers-Danlos Syndrome verified by a mutation of the COL3A1 gene
  • Ages 12-45 year at the time of enrollment
  • Access to a smartphone as well as an additional device with camera and microphone
  • Stable internet access
  • English speaking

Exclusion Criteria:

  • Non-English speakers
  • Any conditions or developmental delays limiting the ability to utilize technology or follow directions.

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: Intervention

Group of up to 20 patients will be randomly allocated into an experimental group at a 1:1 ratio intervention to controls. The experimental group will receive all of the preliminary outcome screening with the additional 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.

placebo comparator: Control

Group of up to 20 patients will be randomly allocated into a control group at a 1:1 ratio for intervention to controls. The control group will receive all of the preliminary outcome screening and will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.

Interventions

Heartmath Intervention

The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. During the initial visit for the intervention group the same assessment will be included, however, they will also receive 10-15 of instruction on a basic Heartmath technique. Group participants will be asked to complete 5-10 minutes of HeartMath techniques 2x daily. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. However, each week the intervention group will receive an addition 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.

Control Group

The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. The initial visit will include an HRV assessment using the HeartMath sensor via the 3-step Protocol developed by the HeartMath Institute. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.

Primary outcome measure

  • Percent Change in Mean Overall Systolic Blood Pressure [ Time Frame: 3 Months ]

Central Contacts and Locations

Central contacts

Shaine A Morris, MD, MPH

832-826-5692shainem@bcm.edu

Jennifer Bogardus, PT, MPT, PhD

713-794-2070jennifer.bogardus@utah.edu

Locations

Texas Children's Hospital

Recruiting

Houston, Texas, United States, 77030

Contacts

Shaine A Morris, MD MPH

832-826-5682shainem@bcm.edu

Jennifer Bogardus, PT, MPT, PhD

713-794-2070jennifer.bogardus@utah.edu

More Information

Sponsor

Baylor College of Medicine

Last update posted

Jul 1, 2024

Last verified

Jun, 2024

Keywords

  • Cardiovascular
  • Mental Health
  • Heart Rate Variability

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Baylor College of Medicine on 2024-07-01.